Report Overview

The Brazil epilepsy market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behaviour, sensations, and sometimes loss of awareness. Seizures are the main symptoms of the epilepsy which usually causes disturbance in persons mental, sensory and motor functions. Tumour, head injuries, stroke, alcohol withdrawal, birth injuries among others are some of the common reason for the epilepsy.



Market Drivers

The increase in the number of accidents and brain injuries and the high rate of post-traumatic epilepsy (PTE) and post-traumatic seizure (PTS) occurrence in patients with brain injuries are the major factors driving the epilepsy treatment market. The increase in funding by Brazilian healthcare system- SUS, to enhance and develop effective drugs and treatments for seizures and rise in the R&D activities to provide advanced healthcare facilities accelerate the epilepsy treatment market growth.

Additionally, growing geriatric population, increasing epilepsy cases, rise in the awareness about the treatment options available among people and price erosion of the treatments positively affect the epilepsy treatment market.

Major epilepsy condition

By condition, the market is bifurcated into epilepsy drug-resistant/intractable epilepsy and others. The drug-resistant epilepsy segment is expected to be a market leader by the end of the forecast period. The advent of rational polytherapy for treating disease with minimal side-effects is expected to produce substantial revenue for the epilepsy market.